Competitive Generic Therapies

5 October 2022 — FDA published final guidance on competitive generic therapies for industry.

This guidance provides a description of the process that applicants should follow to request designation of a drug as a CGT and the criteria for designating a drug as a CGT. It also includes information on the actions FDA may take to expedite the development and review of ANDAs for drugs designated as CGTs. Finally, it provides information on how FDA implements the statutory provision for a 180-day exclusivity period for certain first approved applicants that submit ANDAs for CGTs.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /